ArticleCancer discovery2025
Demographic Trends in NCI-sponsored Early-phase Clinical Trials (2000-2023): A Cohort Study.
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We analyzed demographic trends among patients enrolled in NCI Cancer Therapy Evaluation Program-sponsored early-phase clinical trials during 2000 to 2023. Using a large patient subset (N = 16,609; 15,308 U.S. residents), we assessed enrollment trends via 3-year rolling averages and Joinpoint analysis. U.S. residents were matched to census demographics, rurality, geographic, and poverty data by ZIP code and Surveillance, Epidemiology, and End Results 2022 cancer incidence rates. Enrollment increased among patients aged 65 to 74 (24.6%-32.3%) and 75 to 84 (6.2%-12.4%) and among Hispanic/Latino (4.5%-7.7%), Asian/Pacific Islander (2.2%-4.4%), and non-Hispanic Black (6.1%-7.2%) patients. However, participation remained below cancer incidence rates for Hispanic/Latino and non-Hispanic Black patients and was negligible among American Indian and Alaska Native populations. Representation improved significantly following the 2014 implementation of the Experimental Therapeutics Clinical Trials Network, accompanied by a reduction in the average distance between patients' residences and enrolling institutions. SIGNIFICANCE: This is the first study that evaluates the demographic representation trends in early-phase clinical trials spanning over two decades. It provides valuable insights to help broaden participation in future trials and inform meaningful policy changes to address persistent gaps in oncology research and clinical care. See related commentary by Hughes Halbert, p. 2194.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.